Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease
Status:
Recruiting
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
This short-term, randomized, placebo-controlled, investigator-initiated trial aims to
establish metabolic improvements in NAFLD subjects by dietary supplementation with cofactors
N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside and serine. Concomitant use of
pivotal metabolic cofactors via simultaneous dietary supplementation will stimulate three
different pathways to enhance hepatic β-oxidation and this study's hypothesis is that this
will result in decreased amount of fat in the liver.
Phase:
Phase 2
Details
Lead Sponsor:
ScandiBio Therapeutics AB
Collaborators:
Göteborg University Helsinki University Central Hospital Koç University Koç University Hospital KTH Royal Institute of Technology Monitor CRO Sahlgrenska University Hospital, Sweden University of Helsinki